| Name | Title | Contact Details |
|---|
capSpire propels energy and commodity businesses forward by blending human ingenuity with deep market expertise to solve complex challenges. Our mission is to deliver transformative solutions that empower businesses to grow, scale, and succeed. With three integrated services—Advisory, Delivery, and Operations and Support—capSpire offers holistic solutions that start with strategy and carry clients seamlessly through to scale. What sets capSpire apart is our ability to connect every stage of the value chain, delivering tailored solutions that integrate technology, processes, and industry insight. From strategy consulting and technology implementation to operational excellence, we strive to ensure that every solution drives measurable impact and uncovers new growth opportunities. At capSpire, we dont just implement solutions; we become an extension of your team. We empower businesses to maximize their investments and push forward—confidently and strategically—into the future. Together, well power forward.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees around the world, the company contributes to sustainable society by providing solutions to the worlds challenges through its three business sectors of Material, Homes, and Health Care.